When does the Gazyva (obinutuzumab) patent expire?
I can’t determine a specific “Gazyva patent expiry” date from the information provided. Patent expiry depends on the country/jurisdiction and on which patent family you mean (for example, primary composition-of-matter versus method-of-use, packaging, or biologic manufacturing-related patents).
Which patents are involved with Gazyva—what “expiry” might refer to?
For a biologic like Gazyva (obinutuzumab), “expiry” commonly gets used to mean different legal milestones, such as:
- the end of patent protection for specific claims (varies by patent and country), and/or
- the end of regulatory exclusivity periods (which are separate from patent terms and also vary by region).
Without the patent numbers, jurisdictions, or the regulatory marker you’re focused on, there isn’t enough data here to map a concrete expiry timeline.
Does patent expiry equal when biosimilars can launch?
Not necessarily. Even if a particular patent term ends, a biosimilar’s entry can still be delayed by:
- other still-in-force patents in the same family (or related families),
- ongoing litigation or settlements, and/or
- regulatory exclusivity rules that block approval or marketing in a given jurisdiction.
What I need to give you a precise expiry date
If you share any of the following, I can help you pin down the likely expiry window more precisely:
- the country/region (e.g., US, EU/UK, Canada, Japan),
- the patent number(s) or family name you’re looking at, or
- whether you mean “first patent expiry,” “all patents expiry,” or “regulatory exclusivity end.”
Fast next step
Tell me which jurisdiction you care about (US or EU/UK is most common), and whether you mean US patents or the broader patent set. Then provide a patent number (or a link/title), and I’ll translate that into an expiry timeline and what it means for biosimilar entry.